KEGG enrichment uncovered the above 6 DEFRGs principally participated in renal cell carcinoma, colorectal cancer, rheumatoid arthritis, breast cancer, IL-17 signaling pathway, endocrine resistance, TNF signaling pathway, oxytocin signaling pathway, mTOR signaling pathway, hepatitis B, NOD-like receptor signaling pathway (Fig. 3a and Supplemental Table 2). This evidence concerns the gene IL17A and breast carcinoma.